Skip to main content

Table 1 Ongoing and terminated active amyloid-beta immunotherapy clinical programs in Alzheimer’s disease

From: Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Name Company Phase Antigen
Affitope AD02 Affiris/GlaxoSmithKline 2 1–6
CAD106 Novartis 2 1–6
Vanutide cridificar Elan/Johnson & Johnson/Pfizer Inc. 2 1–6
ACI24 AC Immune/Bayer Healthcare Pharmaceuticals 1/2 1–15
V950 Merck & Co. 1 Not published
Affitope AD03 Affiris/GlaxoSmithKline 1 Pyroglutamate modified Aβ
UB311 United Biomedical 1 1–14
AN1792 Elan Terminated 1–42
  1. Aβ, amyloid-beta.